Plus therapeutics, inc. (CYTX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Product revenues

-

-

2,689

-

-

-

-

-

-

-

-

Cost of product revenues

-

-

1,318

-

-

-

-

-

-

-

-

Related party

-

-

-

-

-

0

1,845

0

0

590

-

Related party

-

-

-

-

-

-

-

-

-

-

591

Third party

-

-

-

-

-

4,953

5,277

8,709

7,983

7,664

5,246

Product revenues

-

-

-

4,656

4,838

4,953

7,122

8,709

7,983

8,254

5,837

Cost of product revenues

-

-

-

2,170

-

-

-

-

-

-

-

Amortization of intangible assets

-

-

1,225

-

-

-

-

-

-

-

-

Gross profit

-

-

146

-

-

-

-

-

-

-

-

Amortization of intangible assets

-

-

-

545

-

-

-

-

-

-

-

Cost of product revenues

-

-

-

-

3,186

2,940

3,421

4,000

3,837

3,908

3,394

Gross profit (loss)

-

-

-

1,941

1,652

2,013

3,701

4,709

4,146

4,346

2,443

Development revenues:
Development, related party

-

-

-

-

-

0

638

2,882

1,992

2,122

8,840

Development

-

-

-

-

-

0

1,179

2,529

0

0

-

Government contracts and other

6,998

2,983

3,722

6,724

6,821

2,645

3,257

381

21

251

-

Total development revenues

6,998

2,983

3,722

6,724

6,821

-

-

-

-

-

-

Research grant and other

-

-

-

-

-

-

-

-

-

-

53

Total development revenues

-

-

-

-

-

2,645

5,074

5,792

2,013

2,373

8,893

Operating expenses:
Research and development

5,365

5,523

11,678

16,197

19,000

15,105

17,065

13,628

10,904

9,687

12,231

Sales and marketing

468

643

3,593

3,611

2,662

6,406

9,026

9,488

13,560

11,040

6,583

General and administrative

4,822

5,579

7,594

8,563

9,765

15,953

16,031

15,672

14,727

12,570

10,415

In process research and development acquired from Azaya

-

-

1,686

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

4,360

-1,285

-

Change in fair value of warrants

-

-

-

-

-

-

-

-

-

-

4,574

Change in fair value of option liability

-

-

-

-

-

0

2,250

-340

-740

30

-920

Total operating expenses

10,655

11,745

24,551

28,371

23,759

37,095

39,454

38,919

35,571

32,042

32,883

Operating loss

-3,657

-8,762

-20,683

-19,706

-15,286

-32,437

-30,679

-28,418

-29,412

-25,323

-21,547

Other income (expense):
Income (loss) on asset disposal

-

-

-

-

-

42

-257

0

0

-

-

Loss on debt extinguishment

-

-

-

-

-260

0

-708

0

0

-

-

Interest income

55

43

33

19

9

6

4

4

9

9

20

Interest expense

1,855

1,922

2,049

2,592

3,379

4,371

3,396

3,386

2,784

2,052

1,427

Other income (expense), net

-

-

13

233

172

-608

-438

-314

-55

23

-218

Change in fair value of warrants

-3,407

-2,233

0

-

-7,668

-369

-418

-209

-

-

-

Issuance cost of warrants

1,233

470

0

-

-

-

-

-

-

-

-

Gain on Puregraft divestiture

-

-

-

-

-

0

4,453

0

0

-

-

Gain on previously held equity interest in joint venture

-

-

-

-

-

0

4,892

0

0

-

-

Equity loss from investment in joint venture

-

-

-

-

-

0

-48

-165

-209

-151

-44

Total other income (expense)

374

-116

-2,003

-2,340

-3,458

-4,931

4,502

-3,861

-3,039

-2,171

-1,669

Loss from continuing operations

-3,283

-8,878

-

-

-

-

-

-

-

-

-

Loss from discontinued operations

-7,604

-3,756

-

-

-

-

-

-

-

-

-

Net loss

-10,887

-12,634

-22,686

-22,046

-18,744

-37,368

-26,177

-32,279

-32,451

-27,494

-23,216

Income (Loss) from continuing operations

-3,283

-8,878

-

-

-

-

-

-

-

-

-

Beneficial conversion feature for convertible preferred stock

554

2,487

3,977

0

661

1,169

0

0

-

-

-

Net loss allocable to common stockholders - continuing operations

-3,837

-11,365

-

-

-

-

-

-

-

-

-

Net loss allocable to common stockholders - discontinued operations

-7,604

-3,756

-

-

-

-

-

-

-

-

-

Net loss allocable to common stockholders

-11,441

-15,121

-26,663

-22,046

-19,405

-38,537

-26,177

-32,279

-

-

-

Basic and diluted net loss per share attributable to common stockholders - continuing operations

-2.77

-65.37

-

-

-

-

-

-

-

-

-

Basic and diluted net loss per share attributable to common stockholders - discontinued operations

-5.49

-21.61

-

-

-

-

-

-

-

-

-

Net loss per share, basis and diluted

-8.27

-86.98

-8.23

-1.28

-2.07

-0.48

-0.39

-0.55

-0.61

-0.60

-

Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders

1,384

173

3,238

17,290

9,386

80,830

67,781

58,679

53,504

45,947

-

Diluted

-

-

-

-

-

-

-

-

-

-

-0.65

Diluted

-

-

-

-

-

-

-

-

-

-

35,939

Comprehensive loss:
Net loss

-10,887

-12,634

-22,686

-22,046

-18,744

-37,368

-26,177

-32,279

-32,451

-27,494

-23,216

Other comprehensive loss – foreign currency translation adjustments

0

-169

129

262

296

444

256

0

0

-

-

Comprehensive loss

-10,887

-12,803

-22,557

-21,784

-18,448

-36,924

-25,921

-32,279

-32,451

-

-

Product [Member]
Revenues

-

-

2,689

-

-

-

-

-

-

-

-

License [Member]
Revenues

-

-

0

-

-

-

-

-

-

-

-